source
- Neurosterix secures $105M Series B to launch phase 2 schizophrenia trialAddex Therapeutics' spinout Neurosterix announced a $105 million Series B financing to fund its upcoming phase 2 trial of NTX-253 for schizophrenia. The round was led by a syndicate of leading lif…
- FDA shelves Commissioner’s National Priority Voucher program ahead of Heidi Overton confirmation voteThe Food and Drug Administration has halted the Commissioner’s National Priority Voucher (CNPV) program as the Senate prepares to vote on Heidi Overton’s nomination as the agency’s next commissione…